Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Kubota, Daisuke ^a,b   Yoshida, Akihiko ^c   Tsuda, Hitoshi ^c   Suehara, Yoshiyuki ^b   Okubo, Taketo ^b   Saito, Tsuyoshi ^b   Orita, Hajime ^d   Sato, Koichi ^d   Taguchi, Takahiro ^e   Yao, Takashi ^b   Kaneko, Kazuo ^b   Katai, Hitoshi ^c   Kawai, Akira ^c   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^e KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ER81; TUMOR MARKER; DNA BINDING PROTEIN; ETV1 PROTEIN, HUMAN; KCTD10 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; VOLTAGE GATED POTASSIUM CHANNEL;

ADULT; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE FUNCTION; GENE SILENCING; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KCTD10 GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR VOLUME; AGED; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROGNOSIS; RISK FACTORS; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893524660     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073896     Document Type: Article

References (26)

1. Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369: 1731-1741. doi:10.1016/S0140-6736(07)60780-6. PubMed: 17512858.
2. Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y et al. (2006) High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37: 1527-1535. doi:10.1016/j.humpath. 2006.07.002. PubMed: 16996566.
3. Agaimy A, Wünsch PH, Hofstaedter F, Blaszyk H, Rümmele P et al. (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31: 113-120. doi:10.1097/01.pas.0000213307.05811.f0. PubMed: 17197927.
4. Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM et al. (2012) Recent advances and novel agents for gastrointestinal stromal tumor (GIST). Hematol Oncol 5: 21. doi:10.1186/1756-8722-5-21. PubMed: 22569033.
5. Lamba G, Gupta R, Lee B, Ambrale S, Liu D (2012) Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol 1: 14. doi:10.1186/2162-3619-1-14. PubMed: 23210689.
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056. doi:10.1056/NEJM200104053441404. PubMed: 11287975.
7. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J et al. (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038. PubMed: 12374669.
8. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D et al. (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307: 1265-1272. doi:10.1001/jama.2012.347. PubMed: 22453568.
9. Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE et al. (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13: 265-274. doi:10.1016/S1470-2045(11)70299-6. PubMed: 22153892.
10. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J et al. (2010) ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467: 849-853. doi:10.1038/nature09409. PubMed: 20927104.
11. Birner P, Beer A, Vinatzer U, Stary S, Höftberger R et al. (2012) MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin Cancer Res 18: 1879-1887. doi: 10.1158/1078-0432.CCR-11-2364. PubMed: 22351694.
12. Suehara Y, Kondo T, Seki K, Shibata T, Fujii K et al. (2008) Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 14: 1707-1717. doi: 10.1158/1078-0432.CCR-07-1478. PubMed: 18347171.
13. Kikuta K, Gotoh M, Kanda T, Tochigi N, Shimoda T et al. (2010) Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol 40: 60-72. doi:10.1093/jjco/hyp125. PubMed: 19815537.
14. Kubota D, Orita H, Yoshida A, Gotoh M, Kanda T et al. (2011) Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities. Jpn J Clin Oncol 41: 1194-1202. doi: 10.1093/jjco/hyr121. PubMed: 21903705.
15. Kubota D, Okubo T, Saito T, Suehara Y, Yoshida A et al. (2012) Validation Study on Pfetin and ATP-dependent RNA Helicase DDX39 as Prognostic Biomarkers in Gastrointestinal Stromal Tumour. Jpn J Clin Oncol, 42: 730-41. PubMed: 22723667.
16. Hasegawa T, Asanuma H, Ogino J, Hirohashi Y, Shinomura Y et al. (2013) Use of potassium channel tetramerization domain-containing 12 as a biomarker for diagnosis and prognosis of gastrointestinal stromal tumor. Hum: Pathol.
17. Hamilton SR, Aaltonen LA (2000) Pathology and Genetics. Tumours of the Digestive System. Lyon: IARC Press.
18. Miettinen M, El-Rifai W, [!(surname)!], [!(surname)!], Lasota J (2002) Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33: 478-483. doi:10.1053/hupa. 2002.124123. PubMed: 12094372.
19. Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T et al. (2002) Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest 82: 663-665. doi:10.1038/labinvest.3780461. PubMed: 12004007.
20. Fisher RA (1922) On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soc 85: 87-94. doi:10.2307/2340521.
21. Fisher RA (1945) A new test for 2 x 2 tables. Nature 156: 388. doi: 10.1038/156388b0.
22. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481. doi: 10.1080/01621459.1958.10501452.
23. Cox D (1972) Regression models and life tables. J R Stat Soc 34: 187-220.
24. Zhou J, Ren K, Liu X, Xiong X, Hu X et al. (2005) A novel PDIP1-related protein, KCTD10, that interacts with proliferating cell nuclear antigen and DNA polymerase delta. Biochim Biophys Acta 1729: 200-203. doi:10.1016/j.bbaexp.2005.05.005. PubMed: 15982757.
25. Wang Y, Zheng Y, Luo F, Fan X, Chen J et al. (2009) KCTD10 interacts with proliferating cell nuclear antigen and its down-regulation could inhibit cell proliferation. J Cell Biochem 106: 409-413. doi: 10.1002/jcb.22026. PubMed: 19125419.
26. Hu X, Yan F, Wang F, Yang Z, Xiao L et al. (2012) TNFAIP1 interacts with KCTD10 to promote the degradation of KCTD10 proteins and inhibit the transcriptional activities of NF-kappaB and AP-1. Mol Biol Rep 39: 9911-9919. doi:10.1007/s11033-012-1858-7. PubMed: 22810651.